Myriad myRisk® Hereditary Cancer Test Demonstrates the Magnitude of Breast and Ovarian Cancer Risk in Nearly 100,000 Patients Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Monday, June 06, 2016

Myriad myRisk® Hereditary Cancer Test Demonstrates the Magnitude of Breast and Ovarian Cancer Risk in Nearly 100,000 Patients



financial news
 June 6, 2016 
 New Studies at the 2016 ASCO Annual Meeting Demonstrate a 2- to 40-Fold Increased Risk

SALT LAKE CITY, June 06, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that two analyses demonstrating the utility of the Myriad myRisk® Hereditary Cancer test will be featured in oral presentations at the 2016 American Society of Clinical Oncology annual meeting. These presentations demonstrate the importance of using a 25-gene panel to evaluate risk for hereditary breast and ovarian cancers.
"Risk assessment for hereditary cancer is expanding with the use of the myRisk Hereditary Cancer 25-gene panel, approximately doubling the rate of mutation detection over BRCA1/2 testing alone. However, in these studies we sought to understand the magnitude of risk across 25 genes," said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetic Laboratories.  "We discovered that mutations in eight genes are associated with a two- to six-fold increase in breast cancer risk and mutations in 11 genes confer a two- to 40-fold increased risk for ovarian cancer. These important findings clarify the risk across diverse genes and support the use of myRisk as part of a clinical risk assessment for patients."
Results of the studies to be presented are described below and abstracts are available at: abstracts.asco.org.
Follow Myriad on Twitter via @MyriadGenetics to stay informed about news and updates from the Company.
myRisk Hereditary Cancer Podium Presentations

Title: Magnitude of invasive breast cancer (BC) risk associated with mutations detected by multiple-gene germline sequencing in 95,561 women.

Presenter:Michael Hall
, Stanford University Cancer Institute

Date:Monday, June 6, 2016, 8:00 - 11:30 a.m.; Discussion 1:15 - 2:30 p.m.

Location: S404, Abstract 1512, Poster Board 335
This study evaluated the magnitude of invasive breast cancer (BC) risk associated with mutations across a 25-gene panel test.  A total of 95,561 patients underwent clinical testing with the myRisk Hereditary Cancer test. Seven percent of patients tested positive for a deleterious mutation. The majority of mutations occurred in BRCA1/2 genes (44 percent) or other genes associated with BC risk (40 percent). There was a significant association with personal BC history and mutations in BRCA1/2, PTEN, TP53, PALB2, CHEK2, BARD1 and ATM. Specifically, estimates ranged from two (ATM, CHEK2, BARD1) to six (BRCA1, PTEN) times increased risk for breast cancer. These findings demonstrate the BC risk across the diverse panel of 25 genes in the myRisk test.

Title: Ovarian cancer risk associated with mutations detected by multiple-gene germline sequencing in 95,561 women.

Presenter:Allison Kurian
, Stanford University Cancer Institute

Date:Monday, June 6, 2016, 9:45 - 11:15 a.m.

Location: E450ab, Abstract: 5510
This study evaluated the magnitude of ovarian cancer (OC) risk with mutations across the 25 genes included in the myRisk Hereditary Cancer panel. Data from 95,561 patients were analyzed to examine the association between deleterious mutations and personal history of OC. The results showed that seven percent of patients tested positive for a deleterious mutation. Among 5,020 women affected by OC, 14 percent had a deleterious mutation (63 percent with BRCA1/2, 9.4 percent in Lynch Syndrome genes and 11.2 percent in other genes associated with OC).  In this study, 11 genes were associated with a significant risk of OC, including the first report of OC risk associated with the ATM geneImportantly, one-third of mutations in patients with OC were in non-BRCA and non-Lynch genes, demonstrating that panel testing with the myRisk test identified a broader spectrum of associated cancers.
About Myriad myRisk® Hereditary Cancer Testing.....

0 comments :

Post a Comment

Your comments?